文献速递系统性红斑狼疮

S1P1受体调节剂cenerimod在中重度系统性红斑狼疮2b期随机临床试验中的药效学研究

Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE.
PubMed 文献 · Ann Rheum Dis · 2025-01-16

基于CARE 2b期试验(NCT03742037),采集基线和治疗6个月后的血样,评估cenerimod 2 mg与4 mg及安慰剂对中重度SLE患者Ⅰ型干扰素、IFN-γ和浆细胞基因表达特征的影响。4 mg cenerimod较安慰剂降低IFN相关蛋白及基因特征生物标志物,且在IFN-1高患者中IFN蛋白下降更明显,4 mg对药效学生物标志物的效应量大于2 mg。

要点

  • cenerimod 4 mg治疗6个月较安慰剂降低IFN相关蛋白和基因特征生物标志物。
  • IFN-1高患者较IFN-1低患者IFN蛋白下降更明显,4 mg可预防从IFN-1低向高状态转变。
  • cenerimod 4 mg对IFN-1、IFN-γ和浆细胞的药效学效应量大于2 mg。

核心结论

  • 本研究进一步表征了cenerimod在SLE患者中的作用机制,并证实cenerimod 4 mg用于中重度SLE 3期临床试验(OPUS-1/-2)的科学依据。

研究设计与样本

  • CARE 2b期随机临床试验(NCT03742037),纳入中重度SLE患者,比较cenerimod 2 mg、4 mg与安慰剂。
  • 采集基线和治疗6个月后的血样,用Ⅰ型干扰素、IFN-γ和浆细胞基因表达特征评估药效学效应,并进行细胞类型去卷积估计细胞丰度。

主要发现

  • 与安慰剂相比,cenerimod 4 mg治疗6个月后降低IFN相关蛋白和基因特征生物标志物。
  • IFN-1高患者较IFN-1低患者IFN蛋白下降更明显。
  • IFN-1高患者中,cenerimod 4 mg治疗6个月后IFN-1评分中位数降低,且与安慰剂相比预防了从IFN-1低向高状态的转变。
  • cenerimod 4 mg对药效学生物标志物IFN-1、IFN-γ和浆细胞的效应量大于cenerimod 2 mg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by autoreactive T and B lymphocytes. Sphingosine-1- phosphate (S1P) is involved in lymphocyte egress from peripheral lymphoid organs into the circulation. In phase 2a clinical trial, the potent, selective S1P1 receptor modulator cenerimod reduced circulating antibody-secreting cells and interferon (IFN)-associated biomarkers. OBJECTIVES: Pharmacodynamic effects of 2 and 4 mg cenerimod were evaluated in the phase 2b clinical trial (CARE) in moderate to severe patients with SLE (NCT03742037). METHODS: Blood samples were collected at baseline and after 6 months of treatment with cenerimod or placebo from CARE. The gene expression signatures for type 1 interferon (IFN-1), IFN-γ and plasma cells were used to assess dose-dependent pharmacodynamic effects of cenerimod. Cell-type deconvolution was performed to estimate cell abundance. RESULTS: Cenerimod 4 mg reduced IFN-associated protein and gene signature biomarkers after 6 months compared with placebo. A larger decrease of IFN proteins was evident in IFN-1 high patients compared with IFN-1 low patients. The median IFN-1 score in the IFN-1 high patients was reduced after 6 months of cenerimod 4 mg and the transition from IFN-1 low to high status compared with placebo was prevented. Cenerimod 4 mg exhibited a larger effect size on the pharmacodynamic biomarkers IFN-1, IFN-γ and plasma cells compared with cenerimod 2 mg. CONCLUSIONS: This study further characterised the mechanism of action of cenerimod in patients with SLE and substantiated the scientific rationale for cenerimod 4 mg in the phase 3 clinical trials in moderate to severe SLE (OPUS-1/-2).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Suffiotti M, Brazauskas P, Keller MP, et al. Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE. Ann Rheum Dis. 2025. PMID: 39919901. doi:10.1136/ard-2024-226547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。